drugset / Trial / NCT00211107

A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation.

NCT00211107 ↗

Phase 3 Completed 1294 enrolled Alza Corporation
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary purpose of the study is to demonstrate that dapoxetine can prolong intravaginal ejaculatory latency time (IELT) compared with placebo in men with premature ejaculation (PE).

Timeline

Start
2003-06
Primary completion
—
Completion
2004-06

Outcome

Met primary endpoint

paper Dapoxetine significantly prolonged IELT (p<0.0001, all doses vs placebo). PMID 16962882 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Dapoxetine Small molecule 30 mg Oral
Subject Dapoxetine Small molecule 60 mg Oral

Indications